Product Details
Place of Origin: Shanghai, China
Brand Name: Orsin
Certification: ISO 13485
Model Number: Cell-Free DNA
Payment & Shipping Terms
Minimum Order Quantity: 1000
Price: Negotiation
Payment Terms: L/C, D/A, D/P, T/T, Western Union
Unlock the future of precision medicine with Orsin Medical Technology's cutting-edge Cell-Free DNA (cfDNA) Testing Solutions. Our advanced, non-invasive technology harnesses the power of circulating cfDNA to deliver highly accurate, real-time insights into genetic abnormalities, cancer detection, prenatal screening, and disease monitoring.
From oncology to reproductive health, Orsin Medical Technology is pioneering the next generation of liquid biopsy - making diagnostics faster, safer, and more accessible.
Attribute | Feature |
---|---|
Technology | Next-generation sequencing (NGS) & AI-powered bioinformatics for ultra-sensitive cfDNA analysis. |
Applications | Cancer detection, prenatal screening, transplant monitoring, infectious disease profiling. |
Sample Type | Non-invasive (peripheral blood draw); minimal sample volume required. |
Turnaround Time | Rapid results (3-7 days), optimized for clinical decision-making. |
Accuracy | >99% specificity; detects low-frequency mutations (0.1% variant allele frequency). |
Coverage | Pan-cancer panels, fetal aneuploidy screening, custom biomarker options. |
Regulatory | CE-marked/IVD-certified (adapt to your compliance status, e.g., FDA pending). |
Integration | Compatible with hospital LIS/EHR systems; cloud-based reporting portal. |
Advantage | Reduces need for invasive biopsies; enables dynamic disease monitoring. |
Scenario: Blood tests for routine diagnostics (CBC, biochemistry, coagulation) in outpatient/inpatient settings.
Adaptability:
Scenario: Rapid analysis of blood gases, electrolytes, and cardiac markers (e.g., troponin) in urgent care.
Adaptability:
Scenario: Genomics (DNA/RNA extraction), proteomics, and drug metabolism research.
Adaptability:
Scenario: Blood component separation (plasma, RBCs, platelets), blood typing, and cross-matching.
Adaptability:
Scenario: Low-volume collection for neonates or patients with fragile veins.
Adaptability:
Scenario: Large-scale screening (e.g., HIV, hepatitis, metabolic syndrome).
Adaptability:
Scenario: Community clinics, home healthcare, and remote area testing.
Adaptability: